Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Catalent | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Catalent

Development and Clinical Services segment up 18% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent

4Q Revenues: $510.1 million (-2%)

4Q Earnings: $153.4 million (earnings were $27.0 million 4Q14)

FY Revenues: $1.8 billion (flat)

FY Earnings: $210.3 million (earnings were $15.2 million FY14)

Comments: Revenue from the Oral Technologies segment was $318.8 million in the quarter, down 8% with improved performance in the softgel and modified release offerings, as well as product-participation related activities. The company recorded a one-time $6 million customer contract settlement within its Zydis business. Revenue from the Development and Clinical Services segment was $124.2 million, up 18% primarily due to the Micron acquisition, as well as to growth in the clinical services and integrated oral solids development and manufacturing offerings, partially offset by declines in clinical trial activity in Europe. Revenue from the Medication Delivery Solutions segment was $70.1 million in the quarter, up 2%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters